Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series.

Literature DB >> 31778004

Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series.

Brendan Kleiboer^1,2, Brenda Nielsen², Alica D Ma^2,3, Yasmina Abajas^1,2, Dougald M Monroe³, Nigel S Key^2,3.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：
Factor IX

Year: 2019 PMID： 31778004 PMCID： PMC6992514 DOI： 10.1111/hae.13896

Source DB: PubMed Journal: Haemophilia ISSN： 1351-8216 Impact factor: 4.287

× No keyword cloud information.

9 in total

1. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.

Authors: Eva Herzog; Stephen Harris; Claire Henson; Andrew McEwen; Sabrina Schenk; Marc W Nolte; Ingo Pragst; Gerhard Dickneite; Stefan Schulte; Sabine Zollner
Journal: Thromb Res Date: 2014-02-22 Impact factor: 3.944

2. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Authors: Elena Santagostino; Uri Martinowitz; Toshko Lissitchkov; Brigitte Pan-Petesch; Hideji Hanabusa; Johannes Oldenburg; Lisa Boggio; Claude Negrier; Ingrid Pabinger; Mario von Depka Prondzinski; Carmen Altisent; Giancarlo Castaman; Koji Yamamoto; Maria-Teresa Álvarez-Roman; Christine Voigt; Nicole Blackman; Iris Jacobs
Journal: Blood Date: 2016-01-11 Impact factor: 22.113

3. Evidence of clinically significant extravascular stores of factor IX.

Authors: D Feng; K A Stafford; G J Broze; D W Stafford
Journal: J Thromb Haemost Date: 2013-12 Impact factor: 5.824

4. Binding of factors IX and IXa to cultured vascular endothelial cells.

Authors: D M Stern; M Drillings; H L Nossel; A Hurlet-Jensen; K S LaGamma; J Owen
Journal: Proc Natl Acad Sci U S A Date: 1983-07 Impact factor: 11.205

5. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.

Authors: Joan M Korth-Bradley; Pablo Rendo; Lynne Smith; Carmen Altisent
Journal: Clin Ther Date: 2016-03-08 Impact factor: 3.393

6. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.

Authors: S Björkman
Journal: Haemophilia Date: 2013-06-04 Impact factor: 4.287

7. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Authors: Elena Santagostino; Claude Negrier; Robert Klamroth; Andreas Tiede; Ingrid Pabinger-Fasching; Christine Voigt; Iris Jacobs; Massimo Morfini
Journal: Blood Date: 2012-08-02 Impact factor: 22.113

8. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.

Authors: Lei Diao; Shuanglian Li; Thomas Ludden; Jogarao Gobburu; Ivan Nestorov; Haiyan Jiang
Journal: Clin Pharmacokinet Date: 2014-05 Impact factor: 6.447

9. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.

Authors: Jenny Chia; Jade Louber; Isabelle Glauser; Shirley Taylor; Greg T Bass; Steve K Dower; Paul A Gleeson; Anne M Verhagen
Journal: J Biol Chem Date: 2018-03-09 Impact factor: 5.157

9 in total

4 in total